about
Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitorsThe PIRO concept: P is for predispositionBench-to-bedside review: fulfilling promises of the Human Genome ProjectDeterminants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter studyHyperoxia toxicity after cardiac arrest: What is the evidence?Near-fatal multiple organ dysfunction syndrome induced by Plasmodium malariaeFrench Intensive Care Society, International congress - Réanimation 2016Proceedings of Réanimation 2017, the French Intensive Care Society International CongressLemierre's syndrome and genetic polymorphisms: a case report.Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.Outcome of severe adult thrombotic microangiopathies in the intensive care unit.Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceEfficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Causes and risk factors of death in patients with thrombotic microangiopathies.High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center.Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.Platelet transfusions in cancer patients with hypoproliferative thrombocytopenia in the intensive care unitSevere imported falciparum malaria: a cohort study in 400 critically ill adults.Plasma thioredoxin levels during post-cardiac arrest syndrome: relationship with severity and outcome.Increased survival of cirrhotic patients with septic shock.Comparison of albicans vs. non-albicans candidemia in French intensive care units.Continuous renal replacement therapy may increase the risk of catheter infection.Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patientsSoluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.The era of genomics: impact on sepsis clinical trial design.Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial.Critical role of cRel subunit of NF-κB in sepsis survival.Group A Escherichia coli-related purpura fulminans: an unusual manifestation due to an unusual strain?Risk factors for post-ICU red blood cell transfusion: a prospective study.Src-family-tyrosine kinase Lyn is critical for TLR2-mediated NF-κB activation through the PI 3-kinase signaling pathway.Vascular access sites for acute renal replacement in intensive care units.Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis.Timing and causes of death in septic shock.Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.The importance of Toll-like receptor 2 polymorphisms in severe infections."RéaNet", the Internet utilization among surrogates of critically ill patients with sepsis.Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.
P50
Q24794857-D56532BC-823F-4AAE-A70E-25876D23EDF7Q24795198-F8620174-4B18-4DCE-9F03-4A4C540A74A9Q24798503-1576224F-6EB9-4C9E-811D-62F8E01EC92DQ25257344-65527457-8799-4FE1-9C2E-CC9BC0EC45D8Q26752783-AF009C07-F19D-466C-9223-0F29C02F7562Q27488427-91464249-BFF6-488F-92F2-C4418DAC6910Q28550357-B1F707F8-3FDE-4DAB-BD9D-E0D2434B3133Q28564101-BB5F4378-1774-4A23-B906-187BB10C7B70Q33250421-1D071FEC-6937-47E7-A331-142C29A3F9E9Q33361542-591FE204-D0DE-4E83-9B5C-6110C0728624Q33363990-128C8EF9-8167-437F-BB80-DC629324CE36Q33373566-575BE243-853D-4583-9A0E-3DA2308C8EC7Q33389392-85264DBD-B342-44C5-8F41-F62F44F97338Q33397269-7895BCC2-C138-4EF5-BBAB-13BB26B2BF79Q33400172-4A357A05-13D3-4A88-8D6F-C5C0E804DBECQ33401197-6FB8AEE9-39E3-452E-98A2-014EFAB3E817Q33402347-38AC9461-0C99-4BC6-8440-EA167F58FD02Q33407984-D4B38D48-95A2-45B7-A153-CA4AF668B24DQ33426998-E40B0353-7DFF-45D4-B8A3-A68C1560D9B7Q33427993-64134574-121C-4579-9D66-FD8D0961A256Q33719342-2D37C963-F19F-4C8C-B2BD-20B39153FAA3Q33752742-7C26959A-0EA2-44A4-9AC7-9FB2983C95DCQ33754347-EED35B5A-B815-4F82-9FA2-5F655AEFEB0FQ34026915-F0985033-CE97-4D47-9D32-BC60517F5DD6Q34075448-7D449858-7685-4F47-ACB2-1B0A6AC91EFAQ34298828-9BECCE2E-4594-4ED2-94DE-483D97DC9F55Q34633612-610B9DF2-F936-442C-B3D5-79E95906E3D6Q34633623-1F8AED3F-7DC7-4C8E-80CD-7F3A310E3CE6Q34782017-725F7E4E-13B9-431E-BDFD-0A454309DA6DQ34931523-43F96847-65A5-4A59-A4C4-71DD89350C26Q35036371-C23F088F-E524-4925-9EB4-88B8EE18DE14Q35544790-E2C1484C-EAF2-4050-97DB-9A05FE027D33Q35657516-018EB542-84AA-4D94-A3CD-FE65F06AB814Q35692489-1D3B36A9-6453-43F1-B342-4E223305E6AFQ35760660-A60E1B37-E4AE-4848-B33E-8F73436CCF91Q35761868-5214FB07-133D-4F0C-9628-4927C4A2392CQ35775400-1D44C467-8D5B-4E8C-9A6B-46F0A609DB82Q36291696-5F863F13-8D9E-4274-B14F-039F953B1181Q36328361-B6FD22A8-D13F-4477-B822-0F321B34EC10Q36441468-B91C1895-11A3-47BA-A97E-29728CC7EB64
P50
description
onderzoeker
@nl
name
Jean-Paul Mira
@ast
Jean-Paul Mira
@en
Jean-Paul Mira
@es
Jean-Paul Mira
@nl
Jean-Paul Mira
@sl
type
label
Jean-Paul Mira
@ast
Jean-Paul Mira
@en
Jean-Paul Mira
@es
Jean-Paul Mira
@nl
Jean-Paul Mira
@sl
prefLabel
Jean-Paul Mira
@ast
Jean-Paul Mira
@en
Jean-Paul Mira
@es
Jean-Paul Mira
@nl
Jean-Paul Mira
@sl